Athero (Evolocumab)

Athero is a term often associated with atherosclerotic cardiovascular disease treatments, primarily represented by the advanced biological therapy Evolocumab (branded as Repatha). This medication is a PCSK9 inhibitor designed to significantly lower LDL cholesterol.

The drug was developed by Amgen, an American biotechnology pioneer. Manufacturing occurs across a global network of high-tech facilities, primarily in the United States and Ireland, to ensure stringent biological safety standards. As a leading product in modern cardiology, it is managed globally by Amgen, which remains the ultimate owner and distributor through various regional subsidiaries.